Jordana Jampel

DocwireNews

Second-line treatment with S-1 regimen plus liposomal irinotecan (nal-IRI) did not improve progression-free survival (PFS) compared with nal-IRI plus 5-fluorouracil/leucovorin (5-FU/LV) in metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy, according to data presented at the European Society for Medical Oncology Congress 2024.
In an international, multicenter, open-label, 1:1 randomized phase 1-2 trial, patients (n=120) aged 18 years or older with pancreatic adenocarcinoma previously treated with gemcitabine-based chemotherapy were randomly assigned to the S-1 arm or the 5-FU arm.
In phase 1 (n=20), the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) for nal-IRI plus S-1 were determined.
In phase 2, participants received S-1 25 mg/m2 orally twice daily for 14 days, followed by two weeks rest, and nal-IRI 70 mg/m2 intravenous (IV) on days one and 15 every four weeks (n=61) versus nal-IRI 70 mg/m2 followed by LV 400 mg/m2 and 5-FU 2400 mg/m2 IV over 46-hours every two weeks (n=59), until disease progression.
To detect a hazard ratio (HR) of 0.415 with two-sided α=0.05 and 80% power, 120 patients were needed. HR and 95% CI were estimated using a stratified Cox model.
The primary endpoint was PFS, which was a median of 3.5 months for S-1 and 3.7 months for 5-FU (HR, 1.265; 95% CI, 0.838-1.910; P=.26).
Secondary endpoints included overall survival (median 6.0 months for S-1 vs 9.1 months for 5-FU [HR, 1.468; 95% CI, 0.993-2.171; P=.054]) and serious adverse event rate (39% for S-1 vs 19% for 5-FU [P=.029]).
“Second-line treatment with nal-IRI plus S-1 did not improve PFS…OS tended to improve with nal-IRI plus 5-FU/LV,” the researchers wrote.

Anne Marie Morse, DO

Rob Dillard

Dr. Anne Marie Morse Previews Wake Up Narcolepsy's Inaugural Shadows To Light Gala

WUN Shadows to Light Gala

How Public Health Policies Impact Cancer Care, Awareness, and Disparities

Integrated Oncology Now

Cecilia Brown

PHAROS Analysis Evaluates Safety of Encorafenib Plus Binimetinib in Metastatic NSCLC

Non-Small Cell Lung Cancer

Latest News

Second-line nal-IRI: No PFS Improvement With S-1, Promising OS With 5-FU

Pancreatic Cancer

The primary endpoint was PFS, which was a median of 3.5 months for S-1 and 3.7 months for 5-FU.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Career Center

Expert Interviews

Subscribe